SenzaGen AB (SENZA.ST)
SEK 5.08
(3.25%)
SEK 5.08
(3.25%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -14.74 Million SEK | 26.99% |
| 2022 | -20.19 Million SEK | 35.97% |
| 2021 | -31.53 Million SEK | -16.37% |
| 2020 | -27.09 Million SEK | 28.55% |
| 2019 | -37.92 Million SEK | -82.95% |
| 2018 | -20.73 Million SEK | -24.84% |
| 2017 | -16.6 Million SEK | -46.49% |
| 2016 | -11.33 Million SEK | -132.15% |
| 2015 | -4.88 Million SEK | -1225.12% |
| 2014 | 434 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -5.54 Million SEK | -604.83% |
| 2024 Q1 | -1.07 Million SEK | 81.33% |
| 2023 Q4 | -5.76 Million SEK | -87.84% |
| 2023 Q2 | -8.97 Million SEK | -216.87% |
| 2023 FY | -14.74 Million SEK | 26.99% |
| 2023 Q1 | -2.83 Million SEK | 68.51% |
| 2023 Q3 | -3.06 Million SEK | 65.82% |
| 2022 Q2 | -11.67 Million SEK | -106.02% |
| 2022 Q4 | -8.99 Million SEK | -103.28% |
| 2022 FY | -20.19 Million SEK | 35.97% |
| 2022 Q1 | -5.66 Million SEK | 66.97% |
| 2022 Q3 | -4.42 Million SEK | 62.1% |
| 2021 Q2 | -14.04 Million SEK | -100.66% |
| 2021 FY | -31.53 Million SEK | -16.37% |
| 2021 Q4 | -17.16 Million SEK | -99.06% |
| 2021 Q3 | -8.62 Million SEK | 38.59% |
| 2021 Q1 | -6.99 Million SEK | 47.56% |
| 2020 Q1 | -6.46 Million SEK | 71.9% |
| 2020 FY | -27.09 Million SEK | 28.55% |
| 2020 Q4 | -13.34 Million SEK | -88.34% |
| 2020 Q3 | -7.08 Million SEK | 45.09% |
| 2020 Q2 | -12.9 Million SEK | -99.6% |
| 2019 Q3 | -11.36 Million SEK | 39.69% |
| 2019 Q2 | -18.84 Million SEK | -148.01% |
| 2019 Q1 | -7.59 Million SEK | -24.05% |
| 2019 FY | -37.92 Million SEK | -82.95% |
| 2019 Q4 | -23 Million SEK | -102.44% |
| 2018 FY | -20.73 Million SEK | -24.84% |
| 2018 Q1 | -4.24 Million SEK | -0.52% |
| 2018 Q2 | -4.24 Million SEK | 0.0% |
| 2018 Q3 | -6.12 Million SEK | -44.47% |
| 2018 Q4 | -6.12 Million SEK | 0.0% |
| 2017 Q2 | -4.08 Million SEK | 0.0% |
| 2017 FY | -16.6 Million SEK | -46.49% |
| 2017 Q3 | -4.21 Million SEK | -3.26% |
| 2017 Q1 | -4.08 Million SEK | -32.98% |
| 2017 Q4 | -4.21 Million SEK | 0.0% |
| 2016 FY | -11.33 Million SEK | -132.15% |
| 2016 Q3 | -3.07 Million SEK | -18.34% |
| 2016 Q2 | -2.59 Million SEK | 0.0% |
| 2016 Q1 | -2.59 Million SEK | 0.0% |
| 2016 Q4 | -3.07 Million SEK | 0.0% |
| 2015 FY | -4.88 Million SEK | -1225.12% |
| 2014 FY | 434 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AroCell AB (publ) | -59.78 Million SEK | 75.345% |
| Devyser Diagnostics AB (publ) | -56.5 Million SEK | 73.912% |
| Immunovia AB (publ) | -296.46 Million SEK | 95.028% |
| Prostatype Genomics AB (publ) | -39.3 Million SEK | 62.499% |
| Spermosens AB | -10.89 Million SEK | -35.304% |